These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21381981)

  • 21. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
    Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
    Pendri A; Meanwell NA; Peese KM; Walker MA
    Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging patterns and implications of HIV-1 integrase inhibitor resistance.
    Geretti AM; Armenia D; Ceccherini-Silberstein F
    Curr Opin Infect Dis; 2012 Dec; 25(6):677-86. PubMed ID: 23086187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C
    Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational HIV integrase inhibitors in phase I and phase II clinical trials.
    Han Y; Mesplède T; Wainberg MA
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1207-1213. PubMed ID: 28956664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to novel drug classes.
    Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
    Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 integrase inhibitors: an emerging clinical reality.
    Dayam R; Al-Mawsawi LQ; Neamati N
    Drugs R D; 2007; 8(3):155-68. PubMed ID: 17472411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
    Young B; Fransen S; Greenberg KS; Thomas A; Martens S; St Clair M; Petropoulos CJ; Ha B
    Antivir Ther; 2011; 16(2):253-6. PubMed ID: 21447875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
    Charpentier C; Larrouy L; Collin G; Damond F; Matheron S; Chêne G; Nie T; Schinazi R; Brun-Vézinet F; Descamps D;
    AIDS; 2010 Nov; 24(17):2753-5. PubMed ID: 20827161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
    Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
    Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV type 1 coreceptor tropism, CCR5 genotype, and integrase inhibitor resistance profiles in Vietnam: implications for the introduction of new antiretroviral regimens.
    Luu QP; Dean J; Do TT; Carr MJ; Dunford L; Coughlan S; Connell J; Nguyen HT; Hall WW; Nguyen Thi LA
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1344-8. PubMed ID: 22264071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
    Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
    J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.